SuperGen's rubitecan shows promise as HIV treatment

22 July 2001

A newly-published study has provided evidence that SuperGen'sexperimental drug rubitecan can reduce the replication of HIV-1 in human peripheral blood lymphocytes by 95%, as well as induce apoptosis within 24 hours of drug treatment in freshly-infected human lymphocytes, raising the prospects that the drug has potential utility as an alternative or adjunct therapy for HIV infection.

The research has been published in the current issue of the Journal of Medical Virology. Rubitecan is an orally-active camptothecin analog that is currently in late-stage clinical trials for treating advanced pancreatic cancer (Marketletters passim).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight